文献速递肿瘤 PET/CT

治疗后正电子发射断层扫描-计算机断层扫描对浆母细胞淋巴瘤的预后具有高度预测价值

Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-20

该研究纳入2005-2015年间在淋巴瘤研究协会中心新诊断的35例浆母细胞淋巴瘤患者,所有患者基线FDG高摄取,均接受蒽环类为基础的一线化疗并在治疗结束时行PET/CT评估。按Lugano标准五点法分析,80%达完全代谢缓解(CMR),20%未达CMR(部分代谢缓解9%、疾病稳定6%、疾病进展6%)。一线化疗后达CMR可预测更高的无事件生存(p<0.0001)和总生存(p=0.0006)。

要点

  • 浆母细胞淋巴瘤患者基线FDG摄取均为阳性。
  • 治疗结束PET/CT示80%达完全代谢缓解(CMR)。
  • 一线化疗后CMR预测更高无事件生存(p<0.0001)和总生存(p=0.0006)。

核心结论

  • 本研究证实浆母细胞淋巴瘤亚型具有FDG高摄取,PET/CT在侵袭性淋巴瘤化疗结束后再分期中有用。
  • 治疗结束PET/CT可预测浆母细胞淋巴瘤患者治疗后的结局。

研究设计与样本

  • 回顾性纳入2005-2015年间淋巴瘤研究协会中心新诊断的浆母细胞淋巴瘤患者。
  • 纳入条件为分期时和治疗结束时均行PET/CT且接受蒽环类为基础一线治疗,共35例符合。
  • 治疗结束PET/CT采用Lugano标准五点法视觉分析,分为完全代谢缓解(CMR)与未达CMR(含部分代谢缓解、疾病稳定、疾病进展)。

主要发现

  • 中位随访34个月(范围2.8-120个月)。
  • 所有患者诊断时FDG摄取均为阳性。
  • 80%患者达CMR,20%未达CMR,其中部分代谢缓解9%、疾病稳定6%、疾病进展6%。
  • 一线化疗后达CMR预测更高的无事件生存(p<0.0001)和总生存(p=0.0006)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B cell lymphomas (DLBCL) clinically characterized by a poorer prognostic. Few clinical and imaging data are available and derived from pooled case reports and small series. The aim of the study was to evaluate the FDG avidity at baseline and the utility of 18-Fluorodeoxyglucose (FDG) positron-emission-tomography/computed-tomography (PET/CT) for staging and response assessment. METHODS: Patients with newly diagnosed PBL seen at Lymphoma Study Association centers during the period 2005-2015 were included if they underwent a PET/CT at staging and at the end of treatment (eotPET) and had received an anthracycline-based first line therapy. EotPET scans were analyzed using the 5-point-scale visual analysis in accordance with Lugano criteria. Patients were classified in complete metabolic response (CMR) or no-CMR including partial metabolic response (PMR), stable disease (SD) and progression disease (PD). EotPET results were assessed for the ability to predict event free survival (EFS) and overall survival (OS). RESULTS: Thirty-five PBL patients fulfilled the inclusion criteria. The median follow-up was 34 months (2.8-120 months). FDG avidity was found in all patients at diagnosis. Most patients (80%) achieved CMR, and 20% were no-CMR including 9% PMR, 6% SD, and 6% PD. A CMR after first line chemotherapy predicted higher EFS (p < 0.0001) and OS (p = 0.0006). CONCLUSIONS: This study confirmed the FDG avidity of PBL subtype and the usefulness of PET/CT scanning in restaging an aggressive lymphoma at the completion of chemotherapy. EotPET can predict outcomes following treatment in patients with PBL.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Al Tabaa Y, Tchernonog E, Faurie P, et al. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 29679112. doi:10.1007/s00259-018-4020-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。